On Apr. 6, 2020, the National Cancer Institute awarded of $14.54 million to Roswell Park Comprehensive Cancer Center to test chemokine modulation incorporating AIM ImmunoTech’s Ampligen as an immuno-modulator as part of a strategy to turn ﾑcold’ tumors into ﾑhot’ tumors. Chemokine modulation is designed to enhance the effectiveness of common immunotherapies and lead to new, life-saving combination therapies for people battling cancer.

The planned clinical trials include two studies in patients with metastatic colorectal cancer, two in advanced ovarian cancer and one in patients with checkpoint-resistant advanced melanoma. Three of the five studies will be conducted at Roswell Park, with the two ovarian cancer studies to be led at UPMC’s Hillman Cancer Center, with participation from Roswell Park. All five studies are expected to open by year-end 2021.